Low prevalence of positive hydrogen breath tests in patients with functional gastrointestinal conditions and hypermobile Ehlers-Danlos syndrome.
functional gastrointestinal disorders
hydrogen breath testing
hypermobile Ehlers-Danlos syndrome
irritable bowel syndrome
small intestinal bacterial overgrowth
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
25
01
2023
received:
29
07
2022
accepted:
07
03
2023
medline:
15
8
2023
pubmed:
30
3
2023
entrez:
29
3
2023
Statut:
ppublish
Résumé
Using hydrogen breath testing (HBT) to diagnose small intestinal bacterial overgrowth (SIBO) remains controversial in patients with functional gastrointestinal (GI) disorders, and unknown in those with hypermobility Ehlers-Danlos syndrome (hEDS). We assessed prevalence of positive HBTs in these groups, evaluated the predictive value of GI symptoms and the potential role of proton pump inhibitors (PPIs) on test results. Sequential patients referred for HBT to a tertiary unit were classified into the following groups: GI maldigestion/malabsorption, GI sensorimotor disorders, hEDS, and functional GI disorders. All underwent standardized HBT, and the yield was assessed against symptoms and PPI use. A total of 1062 HBTs were performed over 3 years (70% female, mean age 48 ± 16 years). Overall, 7.5% (80/1062) patients had a positive HBT. Prevalence of positive HBT was highest in patients with GI maldigestion/malabsorption (17.9%; DOR 16.16, p < 0.001), GI sensorimotor disorders (15.9%; DOR 8.84, p < 0.001), compared to functional GI disorders (1.6%; DOR 1.0) (p < 0.0001). None of the hEDS patients tested positive for HBT. A positive HBT was independently associated with increased age (DOR 1.03; p < 0.001) and symptoms of diarrhea (DOR 3.95; p < 0.0001). Patients on PPIs tended towards a positive HBT than patients off PPIs (16.1% vs 6.9%; DOR 2.47; p < 0.0001). Less than 2% of patients with functional GI disorders, and none of the patients with hEDS had a positive HBT. Pre-test probability was higher in patients with: GI structural or neurological disorders; use of long-term PPIs and symptoms of diarrhea. These criteria may be helpful in making appropriate therapeutic decisions and avoiding unnecessary hydrogen breath testing.
Sections du résumé
BACKGROUND
Using hydrogen breath testing (HBT) to diagnose small intestinal bacterial overgrowth (SIBO) remains controversial in patients with functional gastrointestinal (GI) disorders, and unknown in those with hypermobility Ehlers-Danlos syndrome (hEDS). We assessed prevalence of positive HBTs in these groups, evaluated the predictive value of GI symptoms and the potential role of proton pump inhibitors (PPIs) on test results.
METHODS
Sequential patients referred for HBT to a tertiary unit were classified into the following groups: GI maldigestion/malabsorption, GI sensorimotor disorders, hEDS, and functional GI disorders. All underwent standardized HBT, and the yield was assessed against symptoms and PPI use.
KEY RESULTS
A total of 1062 HBTs were performed over 3 years (70% female, mean age 48 ± 16 years). Overall, 7.5% (80/1062) patients had a positive HBT. Prevalence of positive HBT was highest in patients with GI maldigestion/malabsorption (17.9%; DOR 16.16, p < 0.001), GI sensorimotor disorders (15.9%; DOR 8.84, p < 0.001), compared to functional GI disorders (1.6%; DOR 1.0) (p < 0.0001). None of the hEDS patients tested positive for HBT. A positive HBT was independently associated with increased age (DOR 1.03; p < 0.001) and symptoms of diarrhea (DOR 3.95; p < 0.0001). Patients on PPIs tended towards a positive HBT than patients off PPIs (16.1% vs 6.9%; DOR 2.47; p < 0.0001).
CONCLUSIONS & INFERENCES
Less than 2% of patients with functional GI disorders, and none of the patients with hEDS had a positive HBT. Pre-test probability was higher in patients with: GI structural or neurological disorders; use of long-term PPIs and symptoms of diarrhea. These criteria may be helpful in making appropriate therapeutic decisions and avoiding unnecessary hydrogen breath testing.
Substances chimiques
Hydrogen
7YNJ3PO35Z
Proton Pump Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14570Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol. 2017;112(5):775-784. doi:10.1038/ajg.2017.46
Krajicek EJ, Hansel SL. Small intestinal bacterial overgrowth: a primary care review. Mayo Clin Proc. 2016;91(12):1828-1833. doi:10.1016/j.mayocp.2016.07.025
Grace E, Shaw C, Whelan K, Andreyev HJN. Review article: Small intestinal bacterial overgrowth - prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther. 2013;38(7):674-688. doi:10.1111/apt.12456
Lewis SJ, Franco S, Young G, O'Keefe SJD. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10(4):557-561. doi:10.1046/j.1365-2036.1996.d01-506.x
Posserud I, Stotzer P-O, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(6):802-808. doi:10.1136/gut.2006.108712
Ghoshal UC, Srivastava D. Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. World J Gastroenterol. 2014;20(10):2482-2491. doi:10.3748/wjg.v20.i10.2482
Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55(9):2441-2449. doi:10.1007/s10620-010-1276-4
Chen B, Kim JJW, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018;53(7):807-818. doi:10.1007/s00535-018-1476-9
Shah A, Talley NJ, Jones M, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol. 2020;115(2):190-201. doi:10.14309/ajg.0000000000000504
Ford AC, Spiegel BMR, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279-1286. doi:10.1016/j.cgh.2009.06.031
Zarate N, Farmer AD, Grahame R, et al. Unexplained gastrointestinal symptoms and joint hypermobility: is connective tissue the missing link? Neurogastroenterol Motil. 2010;22(3):252-e78. doi:10.1111/j.1365-2982.2009.01421.x
Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet Part C Semin Med Genet. 2017;175(1):8-26. doi:10.1002/ajmg.c.31552
Lam CY, Palsson OS, Whitehead WE, et al. Rome IV functional gastrointestinal disorders and health impairment in subjects with hypermobility spectrum disorders or hypermobile Ehlers-Danlos syndrome. Clin Gastroenterol Hepatol. 2021;19(2):277-287.e3. doi:10.1016/j.cgh.2020.02.034
Fikree A, Chelimsky G, Collins H, Kovacic K, Aziz Q. Gastrointestinal involvement in the Ehlers-Danlos syndromes. Am J Med Genet Part C Semin Med Genet. 2017;175(1):181-187.
Alomari M, Hitawala A, Chadalavada P, et al. Prevalence and predictors of gastrointestinal Dysmotility in patients with hypermobile Ehlers-Danlos syndrome: a tertiary care center experience. Cureus. 2020;12:e7881. doi:10.7759/cureus.7881
Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. Gut. 1972;13(4):251-256. doi:10.1136/gut.13.4.251
Tennant SM, Hartland EL, Phumoonna T, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun. 2008;76(2):639-645. doi:10.1128/IAI.01138-07
Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784-790. doi:10.1001/archinternmed.2010.89
Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047-2056. doi:10.1111/j.1572-0241.2007.01275.x
Bouwknegt M, van Pelt W, Kubbinga ME, Weda M, Havelaar AH. Potential association between the recent increase in campylobacteriosis incidence in The Netherlands and proton-pump inhibitor use - an ecological study. Eurosurveillance. 2014;19(32):20873. doi:10.2807/1560-7917.ES2014.19.32.20873
Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001-1010. doi:10.1038/ajg.2012.179
Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367(9528):2086-2100. doi:10.1016/S0140-6736(06)68932-0
McDonald EG, Milligan J, Frenette C, Lee TC. Continuous proton pump inhibitor therapy and the associated risk of recurrent clostridium difficile infection. JAMA Intern Med. 2015;175(5):784-791. doi:10.1001/jamainternmed.2015.42
Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33(9):1059-1067. doi:10.1111/j.1365-2036.2011.04625.x
Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: A systematic review. Dig Dis Sci. 2010;55(9):2431-2440. doi:10.1007/s10620-009-1076-x
Parkman HP, Urbain JLC, Knight LC, et al. Effect of gastric acid suppressants on human gastric motility. Gut. 1998;42(2):243-250. doi:10.1136/gut.42.2.243
Goddard AF, Spiller RC. The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Aliment Pharmacol Ther. 1996;10(1):105-109. doi:10.1111/j.1365-2036.1996.tb00183.x
Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53(1):27-36. doi:10.1007/s00535-017-1371-9
Revaiah PC, Kochhar R, Rana SV, et al. Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics. JGH Open. 2018;2(2):47-53. doi:10.1002/jgh3.12045
Drossman DA, Hasler WL. Rome IV - Functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016;150(6):1257-1261. doi:10.1053/j.gastro.2016.03.035
Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60(3):334-340. doi:10.1136/gut.2009.205476
Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol. 2008;103(4):958-963. doi:10.1111/j.1572-0241.2008.01785.x
Corazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 1990;98(2):302-309. doi:10.1016/0016-5085(90)90818-L
Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978-2990. doi:10.3748/wjg.v16.i24.2978
Takakura W, Pimentel M. Small intestinal bacterial overgrowth and irritable bowel syndrome - an update. Front Psychiatry. 2020;11:664. doi:10.3389/fpsyt.2020.00664
Erdogan A, Rao SSC, Gulley D, Jacobs C, Lee YY, Badger C. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil. 2015;27(4):481-489. doi:10.1111/nmo.12516
Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SSC. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther. 2013;37(11):1103-1111. doi:10.1111/apt.12304
Algera JP, Colomier E, Melchior C, et al. Associations between postprandial symptoms, hydrogen and methane production, and transit time in irritable bowel syndrome. Neurogastroenterol Motil. 2022;35:e14482. doi:10.1111/nmo.14482
Simrén M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut. 2006;55(3):297-303. doi:10.1136/gut.2005.075127
Hirakawa M, Iida M, Kohrogi N, Fujishima M. Hydrogen breath test assessment of orocecal transit time; comparison with barium meal study. Am J Gastroenterol. 1988;83(12):1361-1363. doi:10.1111/j.1572-0241.1988.tb02269.x
Hammer HF, Fox MR, Keller J, et al. European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus. United Eur Gastroenterol J. 2022;10(1):15-40. doi:10.1002/ueg2.12133
Miller MA, Parkman HP, Urbain JLC, et al. Comparison of scintigraphy and lactulose breath hydrogen test for assessment of orocecal transit. Lactulose accelerates small bowel transit. Dig Dis Sci. 1997;42(1):10-18. doi:10.1023/A:1018864400566
Abbasi MH, Zahedi M, Darvish Moghadam S, Shafieipour S, HayatBakhsh AM. Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in Iran. Middle East J Dig Dis. 2015;7(1):36-40.
Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483-490. doi:10.1016/j.cgh.2012.12.011
Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8(6):504-508. doi:10.1016/j.cgh.2009.12.022
Gandhi A, Shah A, Jones MP, et al. Methane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: A systematic review and meta-analysis. Gut Microbes. 2021;13(1):1933313. doi:10.1080/19490976.2021.1933313
Giamarellos-Bourboulis EJ, Pyleris E, Barbatzas C, Pistiki A, Pimentel M. Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. BMC Gastroenterol. 2016;16(1):67. doi:10.1186/s12876-016-0484-6
Chu H, Fox M, Zheng X, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome: clinical characteristics, psychological factors, and peripheral cytokines. Gastroenterol Res Pract. 2016;2016:1-8. doi:10.1155/2016/3230859
Spiegel BMR, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008;103(12):2972-2976. doi:10.1111/j.1572-0241.2008.01992.x
Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol. 2003;98(11):2454-2459. doi:10.1111/j.1572-0241.2003.07699.x
Nelson AD, Mouchli MA, Valentin N, et al. Ehlers Danlos syndrome and gastrointestinal manifestations: a 20-year experience at Mayo Clinic. Neurogastroenterol Motil. 2015;27(11):1657-1666. doi:10.1111/nmo.12665
Aziz I, Palsson OS, Törnblom H, Sperber AD, Whitehead WE, Simren M. The prevalence and impact of overlapping Rome IV functional gastrointestinal disorders on somatisation, quality of life, and healthcare utilisation: results from a three-country general population study. Gastroenterology. 2017;152(5):S116-S117. doi:10.1016/s0016-5085(17)30728-x
Dhingra R, Bascom R, Thompson E, Francomano CA, Schubart JR. Gastrointestinal medication burden among persons with the Ehlers-Danlos syndromes. Neurogastroenterol Motil. 2021;33(7):e14077. doi:10.1111/nmo.14077
Szigethy E, Knisely M, Drossman D. Opioid misuse in gastroenterology and non-opioid management of abdominal pain. Nat Rev Gastroenterol Hepatol. 2018;15(3):168-180. doi:10.1038/nrgastro.2017.141
Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115(2):165-178. doi:10.14309/ajg.0000000000000501